Total
0
Shares
Kalytera Therapeutics receives positive results from drug study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BriaCell Therapeutics Corp (BCT) has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share
  • The over-allotment option resulted in additional gross proceeds of approximately US$3.7 million
  • Net proceeds from the offering will be allocated to fund clinical trials and research and development
  • BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer
  • BriaCell Therapeutics Corp (BCT) is down 26.25 per cent, trading at C$4.72 per share at 2 pm ET

BriaCell Therapeutics Corp (BCT) has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share.

The over-allotment option granted in connection with the company's recent public offering resulted in additional gross proceeds of approximately US$3.7 million.

Total gross proceeds for the public offering increased to approximately US$28.7 million.

ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.

Net proceeds from the offering will be allocated to fund clinical trials and research and development and for general working capital and general corporate purposes.

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. 

BriaCell Therapeutics Corp (BCT) is down 26.25 per cent, trading at C$4.72 per share at 2 pm ET.

More From The Market Herald
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.
VitalHub (TSXV:VHI) signs multi-year contract with Hampshire Hospitals NHS Foundation Trust

" Skylight Health Group (TSXV:SLHG) acquires Pennsylvania Clinic Group

Skylight Health Group Inc. (SLHG) executes the definitive agreements to acquire a controlling interest in Aspire Health Concepts, Inc.